Jaka jest cena za Probi AB (publ) (PROB)

Cena za Probi AB (publ) (PROB) wynosi $38.87

Jaka jest kapitalizacja rynkowa dla Probi AB (publ) (PROB)

Kapitalizacja rynkowa dla Probi AB (publ) (PROB) wynosi $442.88M

Zyski Probi AB (publ) (PROB)

Probi AB (publ) specializes in the research, development, manufacturing, marketing, and distribution of probiotics for the health, pharmaceutical, and food sectors. The company's scientific endeavors primarily focus on areas such as gastrointestinal, digestive, immune, and bone health, as well as iron absorption, and the specific health requirements of children, women, and seniors. Their product range includes dietary supplements and various food and beverage applications, offered in diverse formats like capsules, tablets (including chewable), spheres, powders, and an array of drinks such as fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's products are sold in approximately 40 countries globally. The company also fosters collaborations, including a partnership with Örebro University for exploring needle-free vaccines and with La Trobe University for a clinical trial assessing the effects of Probi Osteo in Australian women. Established in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$1.76B	-	IN
Galderma Group AG GALD.SW	-	-	CH

Firma

Zyski

Różnica w zyskach

Kraj